Lupin gets green light from FDA for generic Hyzaar, Cozaar
BALTIMORE, Md. Lupin Pharmaceuticals received regulatory approval last week for its generic antihypertensive agents, the drug maker said.
Lupin was granted final approval for hydrochlorothiazide-losartan potassium and losartan potassium, the generic versions of Merck’s Hyzaar and Cozaar.
Hyzaar and Cozaar had combined annual sales of approximately $1.6 billion in the United States, based on IMS sales data for the 12 months ended in June.
Express Scripts looks to curb nonadherence among patients
ST. LOUIS Pharmacy benefit manager Express Scripts said it has created a way to accurately predict which patients were most at risk of not adhering to their medications.
The PBM announced Monday that it had created a computer model that could predict whether a patient would fail to take medications as prescribed up to a year in advance, allowing early intervention to improve adherence. The company said patent protection for the model is pending. According to Express Scripts’ 2009 Drug Trend Report, nonadherence results in $106 billion being wasted on increased medical costs every year.
“The problem of nonadherence isn’t new — it’s easy to walk through a hospital and identify people who would not be there if they had simply taken their medications,” Express Scripts chief medical officer Steven Miller said. “But our new predictive models allow us to do something that wasn’t possible before: better identify those patients before they run into trouble and tailor practical, patient-centric solutions that target the specific factors that put them at risk for nonadherence.”
Alcon introduces new lubricant eye drops
HUENENBERG, Switzerland Alcon on Monday announced the launch of Systane Balance lubricant eye drops, formulated with HP Guar, borate, sorbitol, propylene glycol and Alcon’s exclusive LipiTech System — an emulsion technology of mineral oil and an anionic phospholipid. The new eye drop is designed to restore the lipid layer and the natural tear film to allow for relief of dry-eye symptoms.
“We are dedicated to applying scientific rigor to discover treatments for chronic conditions, such as dry eye,” stated Sabri Markabi, Alcon chief medical officer and SVP research and development. “[For example], meibomian gland dysfunction is a significant cause of dry eye symptoms, and now patients who suffer from dry eye associated with MGD can use Systane Balance to restore their lipid layer, re-establish their natural tear film and maintain their tear film stability.”
MGD is the most common cause of evaporative dry eye, with an estimated 50% of dry-eye patients experiencing MGD. Physicians observed an association between the use of Systane Balance and better tear film stabilization, as well as an improvement in the thickening of the lipid layer, which are desirable characteristics in treating dry eye. Unlike some other drops where blurring may be a concern, patients reported minimal blur after instilling drops of Systane Balance, the company stated.